IFNA2 and infection: In particular, the ability of SLR14 to elicit IFN-β is ideal, as it enables early medical intervention for COVID-19 patients with preexisting autoantibodies against one or multiple subtypes of IFN-α, who are particularly susceptible to prolonged viral replication and severe disease after infection with SARS-CoV-2 (Meffre and Iwasaki, 2020).